ESR1 and breast carcinoma: Indeed, our method allowed identification of estrogen target genes involved in each of these transitions, providing for the first time a genetic explanation also for the dynamics of breast cancer cell responses to antiestrogen drugs, such as those described for the selective estrogen receptor down-regulator ICI 182,780/Faslodex, a pure antihormone used for treatment of these tumors [28].